Early monitoring of response to neoadjuvant chemotherapy in breast cancer with F-FDG PET/CT: defining a clinical aim.

MLA

Groheux, David, et al. “Early Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer with F-FDG PET/CT: Defining a Clinical Aim.” European Journal of Nuclear Medicine & Molecular Imaging, vol. 38, no. 3, Mar. 2011, pp. 419–25. EBSCOhost, https://doi.org/10.1007/s00259-010-1660-5.

APA

Groheux, D., Giacchetti, S., Espié, M., Rubello, D., Moretti, J., & Hindié, E. (2011). Early monitoring of response to neoadjuvant chemotherapy in breast cancer with F-FDG PET/CT: defining a clinical aim. European Journal of Nuclear Medicine & Molecular Imaging, 38(3), 419–425. https://doi.org/10.1007/s00259-010-1660-5

Chicago

Groheux, David, Sylvie Giacchetti, Marc Espié, Domenico Rubello, Jean-luc Moretti, and Elif Hindié. 2011. “Early Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer with F-FDG PET/CT: Defining a Clinical Aim.” European Journal of Nuclear Medicine & Molecular Imaging 38 (3): 419–25. doi:10.1007/s00259-010-1660-5.